This is a preview of subscription content, log in to check access.
We’re sorry, something doesn't seem to be working properly.
Dewilde S, Turk F, Tambour M, Sandström T.The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Current Medical Research and Opinion 22: 1765-1776, No. 9, Sep 2006
About this article
Cite this article
Omalizumab worth it in severe persistent asthma. Pharmacoecon. Outcomes News 515, 12 (2006). https://doi.org/10.2165/00151234-200605150-00042
- Incremental Cost Effectiveness Ratio
- Allergic Asthma
- Persistent Asthma